ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response

Author:

Bakr Ali1ORCID,Corte Giuditta Della1,Veselinov Olivera1,Kelekçi Simge1,Chen Mei-Ju May1,Lin Yu-Yu1,Sigismondo Gianluca2ORCID,Iacovone Marika1,Cross Alice1,Syed Rabail1,Jeong Yunhee1ORCID,Sollier Etienne1,Liu Chun- Shan1,Lutsik Pavlo1,Krijgsveld Jeroen23,Weichenhan Dieter1ORCID,Plass Christoph14ORCID,Popanda Odilia1,Schmezer Peter1

Affiliation:

1. Division of Cancer Epigenomics, German Cancer Research Center (DKFZ) , INF280, 69120 Heidelberg , Germany

2. Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ) , INF581, 69120 Heidelberg, Germany

3. Heidelberg University, Medical Faculty , Heidelberg , Germany

4. German Cancer Consortium (DKTK) , INF280, 69120  Heidelberg , Germany

Abstract

Abstract AT-rich interaction domain protein 1A (ARID1A), a SWI/SNF chromatin remodeling complex subunit, is frequently mutated across various cancer entities. Loss of ARID1A leads to DNA repair defects. Here, we show that ARID1A plays epigenetic roles to promote both DNA double-strand breaks (DSBs) repair pathways, non-homologous end-joining (NHEJ) and homologous recombination (HR). ARID1A is accumulated at DSBs after DNA damage and regulates chromatin loops formation by recruiting RAD21 and CTCF to DSBs. Simultaneously, ARID1A facilitates transcription silencing at DSBs in transcriptionally active chromatin by recruiting HDAC1 and RSF1 to control the distribution of activating histone marks, chromatin accessibility, and eviction of RNAPII. ARID1A depletion resulted in enhanced accumulation of micronuclei, activation of cGAS-STING pathway, and an increased expression of immunomodulatory cytokines upon ionizing radiation. Furthermore, low ARID1A expression in cancer patients receiving radiotherapy was associated with higher infiltration of several immune cells. The high mutation rate of ARID1A in various cancer types highlights its clinical relevance as a promising biomarker that correlates with the level of immune regulatory cytokines and estimates the levels of tumor-infiltrating immune cells, which can predict the response to the combination of radio- and immunotherapy.

Funder

German Cancer Research Center

German Research Foundation

Erasmus

Publisher

Oxford University Press (OUP)

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3